BioAge Labs, Inc. (BIOA)
(Delayed Data from NSDQ)
$4.44 USD
+0.02 (0.45%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $4.45 +0.01 (0.23%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, BioAge Labs, Inc. has a market cap of $158.46M, which represents its share price of $4.42 multiplied by its outstanding shares number of 35.85M. As a small-cap company, BIOA's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
BIOA 4.44 +0.02(0.45%)
Will BIOA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BIOA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIOA
BioAge Labs, Inc. (BIOA) Loses -67.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More
BIOA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BIOA
BioArtic: Latest data presented at AAIC 2025 reinforces lecanemab's clinical effect with ...
Lecanemab four-year efficacy and safety data to be presented at AAIC 2025 | BIOA Stock News
The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan ...
BIOA Crosses Above Average Analyst Target